CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
TA-7284 Low +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01512849
NCT01512849Phase 1Completed

An Open-Label, Randomized, 2 Way Crossover, Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

Tanabe Pharma Corporation·interventional·Posted Jan 19, 2012·Updated Jan 8, 2026

In Brief

A Phase 1 clinical trial evaluating TA-7284 Low and TA-7284 High for Type 2 Diabetes Mellitus. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the PK/PD and safety of TA-7284 in patients with type 2 diabetes mellitus who have moderate renal impairment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 19, 2012
Enrollment StartJan 1, 2012
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 14.5 years ago

Interventions

TA-7284 Lowdrug

Low

TA-7284 Highdrug

High